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Introduction
Notch signaling plays critical roles during cell-fate decisions in numerous biological contexts during development and into adulthood (Kopan and Ilagan 2009; Bray 2016; Aster et al. 2017) . Dysregulation of Notch signaling causes human diseases such as Alagille syndrome, CADASIL and T cell leukemia. The core components of this pathway in mammals include four Type-I transmembrane Notch receptors (NOTCH1-4) and five Type-I transmembrane canonical ligands (Delta-like ligand (DLL) 1, 3 or 4, and JAGGED1 or 2). Ligand binding triggers activation of Notch receptors, which leads to proteolytic liberation of the intracellular domain of Notch (NICD) and its nuclear translocation, which activates transcription of Notch downstream targets such as HES and HEY family genes.
O-fucose and O-glucose modifications on the Notch extracellular domain (NECD) act as key regulators of Notch activation (Haltom and Jafar-Nejad 2015; Takeuchi and Haltiwanger 2014) . The NECD contains up to 36 tandem epidermal growth factor-like (EGF) repeats which can be modified with O-linked fucose, glucose or N-acetylglucosamine (GlcNAc) (Haltom and Jafar-Nejad 2015; Takeuchi and Haltiwanger 2010) . Addition of O-fucose to EGF repeats is catalyzed by protein O-fucosyltransferase 1 (POFUT1) in mammals (Ofut1 in Drosophila) (Wang et al. 2001) . Genetic and biochemical studies have shown that O-fucosylation is essential for Notch function in both flies and mice (Okajima and Irvine 2002; Sasamura et al. 2003; Shi and Stanley 2003) . The Fringe family of β3-GlcNAc-transferases elongates O-fucose monosaccharides, providing an additional layer of regulation for Notch receptor activation (Bruckner et al. 2000; Kakuda and Haltiwanger 2017; Moloney et al. 2000) .
Although over 100 potential targets contain the consensus sequence for O-fucose modification by POFUT1 (Schneider et al. 2017) , elimination of Pofut1 results in embryonic lethality in mice with severe Notch-like phenotypes including defects in somitogenesis, cardiogenesis, vasculogenesis and neurogenesis (Shi and Stanley 2003) . Cax mice have an insertion into the fourth exon of Pofut1 resulting in a hypomorphic allele (~25% of WT mRNA levels) and exhibit defective somitogenesis, a process dependent on Notch signaling (Schuster-Gossler et al. 2009 ). This indicates that certain tissues (e.g., presomitic mesoderm) appear to be more sensitive to expression levels of POFUT1 than others in mice. Additionally, a chaperone-like enzymatic activity-independent function for POFUT1 has been identified in Drosophila (Okajima et al. 2005) . Finally, recent studies have shown that POFUT1 haploinsufficiency is linked to an adult-onset Dowling Degos disease (DDD) with hyperpigmentation defects in humans (Chen et al. 2014; Li et al. 2013) . Thus, the extent to which full POFUT1 enzymatic activity is required for proper Notch signaling in vivo remains unclear.
Here we report a patient displaying severe developmental and functional defects including failure to thrive, global developmental delay, hypotonia, aortic coarctation, coagulation factor deficiencies and absence of the main portal vein. Exome sequencing identified no clear cause of his disease, but we identified a novel inherited p.Ser162Leu homozygous missense variant in POFUT1 that we reasoned could be causal. However, no functional assessment of this variation on protein function had been determined. Thus, we sought to delineate the functional consequence of the p.Ser162Leu variant. Here we demonstrate that this mutation disrupts the second N-glycosylation site of POFUT1 and significantly reduces its enzymatic activity. Since alterations in N-glycosylation sites are known to be causative in human disease (Vogt et al. 2005) , we eliminated the second site by mutating Asn160 to Gln. Surprisingly, this mutation had little effect on POFUT1 activity, suggesting that loss of the glycan is not responsible for the reduction in activity. The p.Ser162Leu mutant of POFUT1 showed weaker ability to rescue Notch activity in cell-based assays compared to wild type POFUT1, providing strong support that this homozygous variant is likely causal of this patient's syndrome.
Results

Clinical features and identification of the mutation in POFUT1
This proband was seen at 4 years of age in genetics clinic with some manifestations consistent with a congenital disorder of glycosylation (CDG) including global developmental delay, failure to thrive, severe coarctation of the aorta, ventricular septal defect, constipation, short stature, microcephaly, reduced fat pads, low set and posteriorly rotated ears, wide spaced nipples, mild hypotonia and some coagulation factor laboratory abnormalities, although no overt bleeding disorder. Coagulation activity was assessed due to prolonged prothrombin time, and indicated low Factors II (39% of normal), V (46%), VII (12%) and IX (43%), high Factor VIII (270%). In addition, Protein C (14%), anti-thrombin III (48%) and Protein S (76%), and fibrinogen (190 mg/dL, normal range 207-462) were also low. Some of these finds are consistent with a CDG. However, serum transferrin isoelectric focusing, which can be altered by glycosylation, was normal. In addition to his complex issues potentially related to a CDG, he had features not previously associated with a CDG including nodular hyperplasia of the liver with persistent low-grade cholestasis, and portal vein agenesis. He had a normal ophthalmologic exam and normal skeletal survey, with no evidence of vertebral abnormalities. CDG O-glycosylation panel showed elevated T-antigen (2.1 μmol/L, normal 0.22-1.14) and T-antigen/Sialyl Tantigen ratio (0.08, normal 0.00-0.06) which remains unexplained, but was not consistent with any known CDG. Family history was remarkable for consanguinity, which increases likelihood of detecting a homozygous variant underlying a genetic disorder as over 3% of his genome was homozygous by descent. In this case, the proband's mother is the daughter of the proband's father's first cousin (parents are first cousins once removed). We proposed that he may have a previously unrecognized recessive disorder that has phenotypic overlap with known CDG.
Clinical Exome Sequencing (CES) was performed on the patient and both parents at the UCLA Clinical Genomics Center using standard methods and interpretation . No clearly causal de novo, homozygous or compound heterozygous variants were identified. His thorough genetic evaluation revealed no genetic cause for his multisystem disorder, and the patient was consented for data and specimen collection on a UCLA Medical IRB approved protocol to search for a causal novel variant. We observed a homozygous NM_015352.1: c.485C>T variant (p.Ser162Leu) in POFUT1, demonstrated to be heterozygous in both parents ( Figure 1A ). This variant was predicted to disrupt function of the POFUT1 enzyme, but was of uncertain significance. It was reasoned that it was unlikely to cause full loss of function, as both parents would likely have had a diagnosis of the autosomal-dominant DDD. Both parents are healthy. Thus, this variant created an opportunity for functional validation. The broad spectrum of organ systems affected was plausibly related to a disorder of glycosylation and/or abnormal Notch signaling. Based on the primary sequence of POFUT1, the p.Ser162Leu variant altered the consensus sequence for Nglycosylation on POFUT1 from 160-Asn-Lys-Ser-162 to 160-Asn-LysLeu-162 (the asparagine residue predicted to be modified with an N-glycan is underlined), one of the two predicted N-linked consensus sequences in human POFUT1, which occurs in a region outside of the active site according to the recent reports of the structures of human and mouse POFUT1 proteins ( Figure 1B, C) (Li et al. 2017; McMillan et al. 2017) .
The level of POFUT1 mRNA in fibroblasts from the affected patient (CDG402) was normal compared with those from control patients (GM0038 and GM3348) (Figure 2A ). Analysis of POFUT1 protein levels in extracts of patient and control fibroblasts by western blot showed that the POFUT1 levels were comparable ( Figure 2B) ; however, the size of POFUT1 in the fibroblasts from the patient appeared to be smaller than that in controls, presumably due to loss of N-glycosylation at Asn160 of POFUT1. Single N-glycans have a molecular weight of 1.5-3 kDal, consistent with the shift seen on the gel. Removal of all N-glycosylation using PNGase F digestion caused a shift of POFUT1 proteins from the patient and control fibroblasts to approximately the same size ( Figure 2C ), strongly suggesting that wild type POFUT1 was modified with N-glycans at both Asn62 and Asn160 and that the p.Ser162Leu mutant was modified with N-glycans at Asn62, but not at Asn160. In order to examine whether the p. Ser162Leu mutation affects the function of POFUT1 as a glycosyltransferase, we measured enzymatic activity for POFUT1 extracted from patient fibroblasts using bacterially expressed epidermal growth factor-like (EGF) repeat from human coagulation factor IX (FA9) as an acceptor substrate and GDP-[ 3 H]Fuc as a donor substrate ( Figure 2D ). The POFUT1 activity in the fibroblast extracts from the patient was significantly lower than that from control fibroblasts. As a control for ER-associated enzymatic activity, we examined the activity of Protein O-glucosyltransferase 1 (POGLUT1) from these extracts and found no significant difference between the patient and controls ( Figure 2D ). Since the p.Ser162Leu variant did not reduce POFUT1 protein levels significantly ( Figure 2B ), this result suggests that the variant has a direct effect on POFUT1 activity.
Biochemical characterization of the p.Ser162Leu mutant
In order to gain insights into how the loss of N-glycosylation sequon, 160-Asn-Lys-Ser-162, decreases the enzymatic activity of POFUT1, we purified recombinant wild type and p.Ser162Leu mutant POFUT1 from the culture media of transiently transfected HEK293T cells. The yield of wild type POFUT1 was higher than that of the p.Ser162Leu mutant. As expected, the size of the p.Ser162Leu mutant was smaller than that of wild type POFUT1 ( Figure 3A) . Elimination of N-glycosylation using PNGase F digestion caused a shift of both wild type enzyme and the p.Ser162Leu mutant to the same size ( Figure 3B ), consistent with those seen in extracts of patient and control fibroblasts ( Figure 2C ). Using the purified wild type and mutant enzymes, we performed kinetic analyses with varied concentrations of acceptor (FA9 EGF repeat) and donor substrate (GDP-Fuc) ( Figure 3C -F). Wild type POFUT1 showed much higher activity at varied concentrations of EGF repeats compared with the p.Ser162Leu mutant ( Figure 3C , D). Lineweaver-Burke plots of this data set indicated that the p. Ser162Leu mutant had a lower Vmax compared to wild type (1.43 nmol/min/mg vs. 28.6 nmol/min/mg) but a higher Km for FA9 EGF (11.98 μM vs. 1.50 μM) indicating the mutant enzyme has a lower affinity for the acceptor substrate. Interestingly, both wild type and . (B) Molecular structures of wild type and the p.Ser162Leu variant (S162L) of POFUT1. Both forms have a signal peptide (orange), a catalytic domain (green) and a KDEL-like endoplasmic reticulum-retention signal sequence (blue). There are two N-glycan sequons in the catalytic domain of wild type POFUT1. The second sequon is disrupted by the S162L mutation. (C) Localization of two N-glycosylation sequons in the 3D-structure of wild type mouse POFUT1 in complex with GDP (red) and an EGF repeat (yellow) (PDB: 5KXH) (Li et al. 2017) . Asn-67 (first site) and Asn-165 (second site) of mouse POFUT1 that are modified with a GlcNAc residue are highlighted in purple. Image rendered in PyMol. mutant POFUT1 had a similar Km for GDP-Fucose (wild type, 3.58 μM; p.Ser162Leu mutant, 2.39 μM) ( Figure 3E, F) . To analyze the products from these assays and confirm that the p.Ser162Leu mutant retains catalytic activity, we performed overnight incubation and then analyzed the products by mass spectrometry. Both wild type and the p.Ser162Leu mutant added a single fucose to the FA9 EGF repeat, indicating that the p.Ser162Leu mutant has residual enzymatic activity ( Figure S1 ).
To determine whether loss of the N-glycan at Asn160, or the change of Ser162 to Leu, were responsible for the reduced POFUT1 activity, we generated an N-glycosylation site mutant by replacing Asn160 with Gln. The p.Asn160Gln mutant migrated at the same position on SDS-PAGE as p.Ser162Leu ( Figure 3G ), consistent with loss of the N-glycan as Asn160. In contrast, the p.Asn160Gln mutant showed POFUT1 activity comparable to wild type POFUT1 ( Figure 3H ). These results suggest that the p.Ser162Leu mutation itself, not the loss of the N-glycan at Asn160, is the cause of the decreased apparent affinity for acceptor substrate and reduced POFUT1 activity.
The ability of p.Ser162Leu to regulate Notch activity in cells
The clinical features seen in the patient, including defects in neurogenesis, cardiogenesis and vasculogenesis, overlap with some of the Notchlike phenotypes observed in mice lacking Pofut1 (Shi and Stanley 2003) . To examine whether the reduced enzymatic activity observed with the p.Ser162Leu POFUT1 mutant affects Notch activity, we performed cell-based NOTCH1 signaling assays in POFUT1-null U2OS cells in which the Notch activity is profoundly reduced compared with wild type U2OS cells ( Figure 4A ) (McMillan et al. 2017) . As expected, transfection of wild type POFUT1 rescued DLL1 ligand-mediated NOTCH1 activity in POFUT1-null cells ( Figure 4A ). Transfection of the p.Ser162Leu mutant only partially rescued NOTCH1 activity, consistent with its decreased fucosyltransferase activity. DLL1 ligandmediated signaling in wild type U2OS cells was not affected by overexpression of either wild type or mutant POFUT1. To avoid saturation of POFUT1 activity in the cells, we varied the amount of POFUT1 expression plasmid against a constant amount of NOTCH1 plasmid to carefully determine the appropriate NOTCH1:POFUT1 ratio. At the 1:0.1 ratio, the Notch activity upon the overexpression of wild type POFUT1 was significantly lower than those at the 1:0.5 or 1:0.25 ratios ( Figure 4B ). At all ratios tested, the p.Ser162Leu mutant of POFUT1 rescued Notch activity to a significantly lower extent than wild type POFUT1. Western blot analysis revealed that WT and p.Ser162Leu mutant POFUT1 were expressed at similar levels in these cells, consistent with the expression levels of wild type and the p.Ser162Leu mutant of POFUT1 in the patient fibroblasts ( Figure 4C ).
Discussion
In the present study, we investigated a patient with a homozygous p.Ser162Leu missense variant of unknown significance in POFUT1 who showed severe developmental defects including global developmental delay, microcephaly, defects in cardiogenesis and vasculogenesis, failure to thrive with malnutrition, mild liver failure and osteopenia. Some of these disease features are consistent with a Notch defect phenotype. For instance, mutations in JAGGED1 (ALGS1, OMIM # 118450) or NOTCH2 (ALGS2, OMIM # 610205) result in Alagille Syndrome, where patients also display defects in liver and cardiac development, and mutations in NOTCH3 cause the vascular disorder CADASIL (OMIM #125310). We demonstrated that this variant disrupted an N-glycosylation site at Asn160, which is modified in wild type POFUT1, and the variant resulted in significantly lower enzymatic activity compared to wild type controls, although it retained some residual activity. Mutation of Asn160 to Gln did not affect POFUT1 activity, showing that the change of Ser162 to Leu, not loss of the N-glycan, is responsible for loss of POFUT1 activity. Moreover, the p.Ser162Leu mutant of POFUT1 was less able to rescue Notch activity compared with wild type POFUT1, suggesting that some of the phenotypes in the patient may be due to reduced Notch signaling. Very recently, the 3D-structures of human and mouse POFUT1 were reported (Li et al. 2017; McMillan et al. 2017 ). In the structures, the second site Asn160 residue (N165 in mouse POFUT1) is far from the enzyme catalytic center and the predicted EGF binding pocket ( Figure 1C) . Thus, the N-glycans at Asn160 are not likely to be involved directly in the catalytic reaction, consistent with our data comparing activity of wild type and p.Asn160Gln POFUT1. The p.Ser162Leu mutant showed lower Vmax and lower affinity for the acceptor substrate EGF repeat, which is likely due to an allosteric effect caused by the p.Ser162Leu mutation itself. The first N-glycosylation site in POFUT1 is conserved in most bilaterians, while the second site is conserved only in mammals. Analysis of bovine POFUT1 showed that mutation of the second N-glycosylation site only partially reduced the activity of POFUT1, whereas mutation of the first N-glycosylation site reduced the stability of the enzyme, suggesting it might be important for folding (Loriol et al. 2007 ). Asn160 is the second N-glycosylation site in human POFUT1, suggesting differential requirement of N-glycans between POFUT1 proteins from mammalian species. Further work will be needed to determine the precise mechanism by which the p.Ser162Leu mutation decreases the enzymatic activity of POFUT1.
Our observation that the p.Ser162Leu mutation causes significant decrease in POFUT1 activity provides important biological insights into the requirement of POFUT1 activity for Notch signaling in vivo. Homozygous deletion of Pofut1 in mice results in embryonic lethality with Notch-like phenotypes while its heterozygous deletion does not cause any phenotypic difference (Shi and Stanley 2003) . The naturally occurring Cax mouse with~25% of normal mRNA levels of Pofut1 due to retrotransposon insertion showed somitogenesis defects during embryonic development consistent with defects in Notch-dependent processes, suggesting that somitogenesis is particularly sensitive to the expression level of Pofut1 in mice (Schuster-Gossler et al. 2009 ). Our patient bearing the p.Ser162Leu mutation in POFUT1 who had normal protein expression level, but less than 10% biochemical activity, presented with defects in multiple developmental processes, some of which are consistent with the Notch phenotypes, including cardiogenesis, neurogenesis and vasculogenesis. Interestingly, two of the serum proteins with reduced levels, coagulation factors VII and IX, are known to be modified by POFUT1 (Bjoern et al. 1991; Nishimura et al. 1992) , and Protein C has a predicted consensus sequence (Schneider et al. 2017) , suggesting that the reduced activity may be related to reduced POFUT1 activity. Although no vertebral defects were observed in the patient, this might be attributed to differences in the ability to rescue reduced POFUT1 function between mice and humans. Alternatively, the putative chaperone activity of POFUT1, which would not require enzymatic activity, may be more important during somitogenesis than transfer of fucose to Notch. The fact that the p.Ser162Leu mutation resulted in more than 90% loss of enzymatic activity but only partially reduced its ability to activate NOTCH1 is consistent with this idea. Recent studies found causative de novo loss of function mutations in POFUT1, which would be presumed to have 50% abundance and activity, manifest as DDD, a type of rare autosomal-dominant genodermatosis (Chen et al. 2014; Li et al. 2013) . No skin defects were observed in the index patient; however, DDD is an adult onset disease. In the family described here, both parents developed normally, despite carrying the p.Ser162Leu allele, implying there was no dominant negative effect. Thus, this new disorder is manifesting as an autosomal recessive disease. Further, we reason that the residual activity of the p. Ser162Leu POFUT1 may explain why neither parent has any features of DDD. This single patient and parents provide strong evidence of a novel disease syndrome caused by a specific variant in POFUT1 and manifesting only if homozygous. We predict that others with compound heterozygous mutations that alter Ser162 may manifest with a similar syndrome, but note that there are only two heterozygous carriers with relevant Ser162 variants identified in ExAc (Lek et al. 2016 ) including one individual with p.Ser162Trp and another with p.Ser162Ala. Thus, the frequency of individuals with homozygous missense variants affecting Ser162 is reasonably estimated to be less than 1 per billion suggesting an ultrarare human disease phenotype.
Materials and methods
Clinical exome sequencing
Referral for exome sequencing in the Clinical Genomics Center at UCLA was performed as previously described . All procedures followed were in accordance with the ethical standards of the UCLA IRB and proper informed consent was obtained. Briefly, exome capture was performed using Agilent SureSelect Human All Exon 50 Mb kit and 100 bp paired-end sequencing was performed on Illumina HiSEQ2000. In total 14,919,168,144 bases of sequence were generated, resulting in mean 150× coverage within the RefSeq protein coding bases of the human genome and 95% of the known diseasecausing bases were reliably sequenced with at least 10× coverage. Total 21,672 DNA variants were identified within the exome, including 20,616 single nucleotide substitutions and 1056 small deletions/ insertions (1-10 bp).
Cell culture
HEK293T cells (ATCC), DLL1 expressing L-cells (generously provided by Dr. Gerry Weinmaster, UCLA), and U2OS WT and POFUT1 knockout cells (generously provided by Dr. Stephen C. Blacklow, Harvard Medical School) were cultured in DMEM-high glucose (Invitrogen) supplemented with 10% bovine calf serum and 1% penicillin/streptomycin (Invitrogen). Skin-derived fibroblasts were cultured in DMEM (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen) in a humidified atmosphere with 5% CO 2 at 37°C.
qRT-PCR assays for fibroblast extracts RNA was isolated from cells using TRIzol (Thermo Fisher Scientific) according to manufacturer's protocol. RNA was quantified following purification and SuperScript II Reverse Transcriptase (Thermo Fisher Scientific) was used to generate cDNA according to manufacturer's protocol. cDNA was quantified and used for RT-qPCR analysis. The SYBR Green Real-Time PCR kit was used with 1 μg cDNA and 1 μg primers (see below for sequences). For POFUT1, the forward primer was 5′-AACAGCTCTTCAAAGGGAAG-3′ and the reverse primer was 5′-ACAGTTGCCAATAAAGTGGT-3′. For GAPDH, the forward primer was 5′-ACATCGCTCAGACACCATG-3′ and the reverse primer was 5′-ATGACAAGCTTCCCGTTCTC-3′.
Mixtures were added to wells of a 384 well plate and run on the Light Cycler 480 (Roche) for 40 cycles. The 2 -ΔΔCT method was used for analysis of results and samples were normalized to GAPDH. Three independent experiments were performed for each sample (n = 9).
Western blot analysis of cell homogenates
Cell pellets of human fibroblasts were homogenized in TBS containing protease inhibitor cocktail as previously described (FernandezValdivia et al. 2011) . Protein concentrations of the homogenates were measured by using a protein assay (Bio-Rad) with a BSA standard. The samples were separated using SDS-PAGE with a 10% polyacrylamide gel. The gels were transferred to nitrocellulose membranes (Bio-Rad), blocked in PBS with 0.1% Tween 20 (PBS-T) containing 5% skim milk at room temperature for 2 h, and incubated in PBS-T containing rabbit anti-POFUT1 polyclonal antibody (1:1000) (Origene, Catalog #: TA306631) or mouse anti-β-actin antibody (1:5000) (Abcam, Clone: AC-15) at 4°C overnight. After washing with PBS-T three times, the membranes were incubated with HRP-conjugated goat anti-rabbit antibody or goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories) at room temperature for 1 h. After the membrane was washed with PBS-T for 10 min six times, the bands on the membranes were visualized using the ECL method with Western Lightning. PNGase F digestion was performed as previously described (Vasudevan et al. 2015) .
Assays for POFUT1 enzymatic activity
Enzymatic assays for POFUT1 and POGLUT1 activity were performed with cell homogenates as previously described (Takeuchi et al. 2012 
Mass spectrometric analysis
For mass spectral product analysis, enzymatic reactions were performed as described above with 200 μM GDP-Fuc overnight. The resulting products were analyzed by nano LC-MS/MS on an Agilent XCT Ultra ion trap mass spectrometer with a CHIP-Cube interface as previously described (Taylor et al. 2014) . The relative quantities of fucosylated and unglycosylated EGF repeats were analyzed using Agilent ChemStation data analysis software with the extracted ion chromatograms of each ion.
Site-directed mutagenesis of human POFUT1 expression vector
The pSecTag2c expression plasmid encoding N-terminally 6xHis-tagged wild type human POFUT1 lacking the C-terminal RDEF was described previously (Takeuchi et al. 2012) . For the p.Ser162Leu mutant, the corresponding nucleotide mutation was introduced by standard PCR-based site-mutagenesis with this plasmid and two primers. The sequences of the primers were 5′-CAACAAGTTGGAGC TTTTTACAGGCATTTCCTT-3′ and 5′-AAAGCTCCAACTTGTT GAAACTCACATGAAACTGAT-3′. For the p.Asn160Gln mutant, the corresponding nucleotide mutation was introduced by standard PCR-based site-mutagenesis with this plasmid and two primers. The sequences of the primers were 5′-GAGTTTCCAGAAGTCGGAGC TTTTTACAGGCATTTCC-3′ and 5′-CTCCGACTTCTGGAAACTCACATGAAACTGATCCC-3′. Successful incorporation of the mutation was confirmed by direct DNA sequencing.
Protein expression and purification
Recombinant human POFUT1 proteins and mouse XXYLT1 proteins were expressed and purified as previously described (Takeuchi et al. 2012) . Briefly, the expression plasmids that encode wild type, the p.Ser162Leu mutant, or p.Asn160Gln mutant of human POFUT1, or mouse XXYLT1 were transfected in HEK293T cells and the proteins secreted to culture media were affinity-purified using Ni-NTA agarose (QIAGEN). After elution with TBS containing 250 mM imidazole from the column, the proteins were dialyzed against TBS containing 20% glycerol and stored at -80°C until use. The concentrations of purified proteins were quantitated by 10% SDS-PAGE followed by Coomassie staining with bovine serum albumin standards.
Cell-based Notch signaling luciferase reporter assays were overlaid on the U2OS transfectants. After an additional 24 h, cells were lysed and luciferase (Luciferase Assay System, Promega) and β-galactosidase assays were performed, as previously described (Kakuda and Haltiwanger 2017) . At least three biological replicates were performed for each sample.
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